Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy
about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsPositron emission tomography of high-grade gliomas.Detecting tumor progression in glioma: Current standards and new techniques.The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer.From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab TreatmentAdvances in neuro-oncology imaging.Current status and future directions of anti-angiogenic therapy for gliomas18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?Amino acid PET and MR perfusion imaging in brain tumours.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Speeding up PET/MR for cancer staging of children and young adults.Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences.Amino acid PET in neuro-oncology: applications in the clinic.Usefulness of PET Imaging to Guide Treatment Options in Gliomas.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.Imaging melphalan therapy response in preclinical extramedullary myeloma with 18F-FDOPA and 18F-FDG PET.18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q26853308-3BFBBB8F-09AB-4454-B3DD-C33C5F7E1CC9Q31047940-A959E334-1D71-4C99-9686-51322942F0D0Q31132701-5DD69D77-D4A2-407A-BAB2-F7FF5453C360Q31156299-E4E3F6BD-7063-4AAF-BEE2-1A5488B75D7DQ34175347-4C372721-075E-4BAA-A523-928C25EB4CF4Q35679377-FD1B0E60-0C3A-46B8-B088-9DDB974E0414Q36218548-1427758C-CDF2-46B5-8CC6-DB54741DFE9CQ36339461-6052E579-70F1-434F-BBFE-CB1002485910Q36618235-55D2BCA2-269F-4CAA-96ED-EBF59DF52166Q38403271-D0234CF6-C78E-4205-B6E1-F24850CA3917Q38691946-7D665329-25B1-4DBB-A912-51746C3A78B7Q38815396-B6290E8A-F217-4A31-BE6D-452EA849BD36Q39860692-68C69576-3A62-404C-8989-CF105B59D09AQ42234940-349FA8AA-F6E9-43AB-9F71-3F83DDDE5DA9Q47161135-F241513C-66E7-45E9-8237-D25A9A9FAD84Q47560758-0115045E-3C8D-4B6D-8882-0C29F0FF6A5CQ48158155-B4C23CFC-305E-41A4-BB95-7A1909BAB16BQ48271318-D8DCFFA2-A857-44CC-B81E-F9CA10203EBCQ48947048-0F522FBD-1C1F-4D75-BC3D-4C6339505E42Q52149377-43A14004-8974-46DC-8655-B90E47730DD2Q52716405-0C7FA7E3-382C-44A4-8306-2DFB95AB1329Q52801683-D0BE3D93-EEC1-41BD-B35D-72CE809A0B9FQ57177114-020B36A0-B86B-4B5C-941B-618638EF1E67
P2860
Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treatment response evaluation ...... glioma on bevacizumab therapy
@ast
Treatment response evaluation ...... glioma on bevacizumab therapy
@en
type
label
Treatment response evaluation ...... glioma on bevacizumab therapy
@ast
Treatment response evaluation ...... glioma on bevacizumab therapy
@en
prefLabel
Treatment response evaluation ...... glioma on bevacizumab therapy
@ast
Treatment response evaluation ...... glioma on bevacizumab therapy
@en
P2093
P2860
P1476
Treatment response evaluation ...... glioma on bevacizumab therapy
@en
P2093
Benjamin M Ellingson
Cheri Geist
Daniel H S Silverman
David Elashoff
Johannes Czernin
Johannes Schwarzenberg
Michael E Phelps
Timothy F Cloughesy
Tristan Grogan
P2860
P304
P356
10.1158/1078-0432.CCR-13-1440
P407
P577
2014-03-31T00:00:00Z